Related Experiment Videos
A chronotherapeutic approach to effective blood pressure management
1Department of Medicine and Therapeutics, University of Glasgow, Western Infirmary, Glasgow, Scotland, GL 116NT United Kingdom. p.a.meredith@clinmed.gla.ac.uk
Insights
Achieving 24-hour blood pressure control is crucial for preventing organ damage. Telmisartan demonstrates superior sustained blood pressure reduction compared to other angiotensin II receptor blockers.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Major hypertension trials confirm treatment benefits but overlook 24-hour blood pressure control.
- Epidemiological data indicate sustained blood pressure reduction is vital for preventing target organ damage.
Purpose of the Study:
- To evaluate the significance of 24-hour blood pressure control in hypertension management.
- To compare the sustained blood pressure-lowering efficacy of different antihypertensive drug classes.
Main Methods:
- Review of epidemiological evidence and major randomized hypertension trials.
- Analysis of drug characteristics related to trough:peak ratio and 24-hour blood pressure monitoring.
Main Results:
- Current hypertension treatment guidelines may not adequately address the need for sustained blood pressure control.
- Some antihypertensive drugs, including certain angiotensin II receptor blockers, exhibit variability in providing consistent 24-hour blood pressure reduction.
- Telmisartan has shown consistent 24-hour blood pressure reduction, unlike some other angiotensin II receptor blockers.
Conclusions:
- Consistent 24-hour blood pressure control is essential for preventing target organ damage in hypertensive patients.
- Telmisartan offers a favorable profile for sustained blood pressure management compared to other angiotensin II receptor blockers.
Abstract:
The major randomized trials in hypertension have unequivocally demonstrated the benefits of treatment. None of these trials have sought to address the issue of the potential superiority of 24-hour blood pressure control. However, there is a volume of epidemiologic evidence to suggest that prevention of target organ damage requires the sustained reduction of blood pressure throughout the full 24-hour period between doses. Historically, some antihypertensive drugs have been approved for use at high doses to achieve apparent blood pressure control at the end of the once-daily dosing interval. This approach is flawed; attention is focused on this single time point at the end of the dosing interval, without due regard to the antihypertensive response during the rest of the dosing interval. Subsequently, guidelines formulated by the US Food and Drug Administration suggest that all antihypertensive drugs should consistently achieve a trough:peak ratio decline in blood pressure of at least 50%. Evidence suggests that antihypertensive drugs, such as calcium antagonists and angiotensin II receptor blockers, differ in their ability to provide 24-hour blood pressure control. For example, unlike some other angiotensin II receptor blockers, telmisartan provides consistent reduction of blood pressure during the 24-hour period.